Archive | M&A RSS feed for this section

3 Ways to Profit in the Market’s Most Underrated Sector

After rallying 8% just in February, the market’s worst performing sector last year looks like it could become the market’s best performing sector this year. Bret Jensen shares three ways he’s positioning his portfolio and his investments to make money from the massive turnaround.  The amount of questions I am getting about the biotech sector […]

Read more

3 Themes to Watch in the Market’s Top Turnaround Sector

Finding the best returns of the next twelve months usually starts with searching out the stocks and sectors that did the worst in the last twelve. Here’s what to watch in the market’s best bet for big returns in 2017. After underperforming the overall market substantially for some 18 months, the biotech sector appears to […]

Read more

5 Growth Stocks with Major Profit Trends to Bank On

If you’re looking for the next big driver of profit growth in the markets, consider investing in these five stocks that Bret Jensen has identified today. All five have catalysts for growth happening right now, so don’t wait and see which stocks Bret’s recommending today. Snapping up this fast-growing software company might be just the […]

Read more

The Best Way to Trade 2017’s First Major Acquisition

Snapping up this fast-growing software company might be just the spark needed to boost this tech stock to new highs in 2017. With management’s commitment to growing this cash-cow technology veteran now crystal clear, the stock price should start to rise even further.  Could 2017 be the year when IPOs (initial public offerings) are back […]

Read more

3 Reasons Why this Biotech Rally is the Real Deal

After dropping some 20% in 2016, the biotech sector could be set for the rally of a lifetime in 2017 and make current investors a fortune in the process. See why Bret Jensen thinks this rally is for real in today’s article.  The biotech sector was one of the poorest performers in the market in […]

Read more

3 Stocks That are Ripe for a Takeover

By investing in these three mid-cap stocks with emerging growth stories you can greatly increase your chance of owning a stock that gets taken out by a larger player. Especially since their sector is flush with big companies holding loads of cash and looking to buy growth. Biotech had its best weekly performance in more […]

Read more

4 Takeover Targets in the Market’s Hottest Sector

There has been a fast and furious resurgence in M&A in this sector with tens of billions of dollars of deals going down in just the last couple of months. With expectations that dealmaking will continue to increase, consider these four stocks as solid investments with the chance for huge returns if they are purchased […]

Read more

The Next 3 Major Biotech Takeover Targets

After record years for deal volume in both 2014 and 2015 in the biotech and pharma industries, M&A transactions have posted a significant decline in the volume of deals so far in 2016 across these industries. As of late August, transactions based on dollar volume were down almost 65% from the same period in 2015. […]

Read more

4 Likely Biotech Takeover Targets to Buy

After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist. It was a good week for the Biotech Gems portfolio. Progenics Pharmaceuticals (NASDAQ: PGNX) leapt 25% in […]

Read more

3 Undervalued Stocks with Strong Upcoming Catalysts

If all goes well for these three stocks, in the next six months they could be worth over double the prices they currently trade for. Each stock has important, business-defining events that, if positive (and it’s likely they will be), would make their businesses significantly more valuable. I get dozens of questions every week on […]

Read more